The clinical-stage biopharma Acelyrin has appointed Bruce C. Cozadd, co-founder and CEO of Jazz Pharmaceuticals (Nasdaq:JAZZ), to its board of directors.
Cozadd co-founded Jazz Pharmaceuticals in 2003. Last year, the company brought in $3 billion in revenue. Cozadd continues to serve as the company’s chairperson and CEO.
Before taking the helm of Jazz Pharmaceuticals, Cozadd served as the chief operating officer of Alza Corp., which merged with Johnson & Johnson in 2001.
He is currently a member of the board of the Biotechnology Innovation Organization (BIO) and also serves on the boards of two non-profits.
“His success as a biopharma leader has given hope to patients around the world, and his perspectives will help Acelyrin build our capabilities, drive growth for our investors, and realize our vision of accelerating the development of life-changing medicines to help pa…